Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...
President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...
Heidi Overton, a UNM-trained physician with Johns Hopkins general surgery training, was selected for FDA commissioner after ...
How drug pricing, tariffs, and manufacturing decisions are becoming connected. For years, pharmaceutical companies could ...
Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the ...
President Trump moves to nominate Heidi Overton as FDA commissioner, Ron Lanton weighs in on drug pricing's collision with trade policy, and Mohd Haque looks at how pharma leaders are scaling AI ...
Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...
Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated ...
The 340B spread mechanism permits covered entities to retain the difference between discounted acquisition cost and commercial or Medicare reimbursement, incentivizing revenue capture rather than ...
Capital continues to flow toward clinical-stage and platform biotech companies, with a wave of new deals, partnerships, and ...
Silence Therapeutics priced 12,962,963 ADSs at $13.50 for ~$175 million gross, with a 30-day 15% overallotment option and closing targeted around August 13, 2026. AbCellera initiated a $200 million ...
A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results